VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
$27.73M
Mr. David T. Domzalski
28.00
Bridgewater, NJ
Jan 25, 2018
1.09
$1.72
3.24
3.60
-8,083.54%
-0.40
0.00
0.76
32.40
3.27
-131.82%
-114.46%
Similar stocks (16)
Veracyte, Inc.
VCYT
Cidara Therapeutics, Inc.
CDTX
Kronos Bio, Inc.
KRON
Unicycive Therapeutics, Inc.
UNCY
Akari Therapeutics, Plc
AKTX
Longeveron Inc.
LGVN
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Lyra Therapeutics, Inc.
LYRA
Vaccinex, Inc.
VCNX
Pulmatrix, Inc.
PULM
TransCode Therapeutics, Inc.
RNAZ
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00795%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (16)
Veracyte, Inc.
VCYT
Cidara Therapeutics, Inc.
CDTX
Kronos Bio, Inc.
KRON
Unicycive Therapeutics, Inc.
UNCY
Akari Therapeutics, Plc
AKTX
Longeveron Inc.
LGVN
SAB Biotherapeutics, Inc.
SABS
GeoVax Labs, Inc.
GOVX
Lyra Therapeutics, Inc.
LYRA
Vaccinex, Inc.
VCNX
Pulmatrix, Inc.
PULM
TransCode Therapeutics, Inc.
RNAZ
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00795%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%